Abstract 1437P
Background
Tissue biopsy (TIB) is the gold standard for biomarker testing in mNSCLC patients. Although TIB is common, it is associated with potential invasive procedure-related complications. Liquid biopsies are used when tissue is unavailable or insufficient for testing. Studies suggest that TFLB has comparable diagnostic accuracy to TIB for detecting genetic alterations in mNSCLC patients. Liquid biopsies are increasingly used to genotype a tumor in a less invasive manner. This study compared TIB-related complications and healthcare costs with TRB vs. TFLB in mNSCLC patients.
Methods
US administrative claims were assessed retrospectively for patients diagnosed with mNSCLC between July 2016 to June 2021 to identify adult Medicare Advantage or commercially insured patients with ≥2 biopsy claims, and whose first biopsy was tissue-based. The second biopsy defined the cohorts: TRB or TFLB. To control for possible confounding factors, study cohorts were matched 1:1 using propensity-scores (PSM).
Results
The study comprised 470 patients post-PSM, each group had 235 patients. TFLB had a lower TIB-related complication rate and associated healthcare costs compared with TRB (Table). Furthermore, mean number of complication-related healthcare visits were lower for TFLB than TRB group; outpatient visits (0.51 v 1.12, p=0.002), inpatient stays (0.45 v 0.67, p<0.001) and inpatient days (3.49 v 6.60, p=0.002). Table: 1437P
Comparison of outcomes between study cohorts
TFLB (N = 235) | TRB (N = 235) | |
TIB-related complications (%)* | 65.1 | 84.7 |
Pneumothorax* | 17.5 | 46.0 |
Prolonged air leak >5 days* | 1.3 | 11.9 |
Hemorrhage | 14.0 | 18.3 |
Infection* | 23.0 | 31.9 |
Thrombotic complications | 13.2 | 8.5 |
Cardiovascular complications | 38.7 | 42.1 |
Death | 0.4 | 2.6 |
Mean [SD] TB complication-related healthcare costs - US$ | ||
Medical costs* | 8,494 [15,706] | 19,741 [30,641] |
Office visits* | 20 [71] | 51 [219] |
Outpatient visits | 251 [1,672] | 336 [1,562] |
Emergency room visits | 119 [590] | 85 [358] |
Inpatient stays* | 8,076 [15,338] | 18,918 [30,012] |
Other medical costs | 29 [148] | 352 [3622] |
∗P-value <0.05
Conclusions
The analysis suggests that TFLB, compared with traditional TRB, is a method that carries less economic burden and fewer TIB-related complications to detect actionable genetic mutations during mNSCLC diagnostic work-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Optum.
Funding
AstraZeneca.
Disclosure
N.M. Engel-Nitz: Financial Interests, Personal, Stocks/Shares: United Health Group; Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca. A. Shah, J. Apple: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. S. Aslam: Financial Interests, Personal, Stocks/Shares: United Health Group; Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca. L. Le: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca; Financial Interests, Personal, Stocks/Shares: United Health Group. M. Terpenning: Financial Interests, Personal, Financially compensated role: Optum; Financial Interests, Personal, Stocks/Shares: Johnson & Johnson, Stryker.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20